O	0	6	Effect	Effect	NN	B-NP
O	7	9	of	of	IN	B-PP
B-Organism_substance	10	18	platelet	platelet	NN	B-NP
I-Organism_substance	18	19	-	-	HYPH	B-NP
I-Organism_substance	19	23	rich	rich	JJ	I-NP
I-Organism_substance	24	30	plasma	plasma	NN	I-NP
O	31	34	and	and	CC	I-NP
O	35	41	fibrin	fibrin	NN	I-NP
O	42	46	glue	glue	NN	I-NP
O	47	49	on	on	IN	B-PP
O	50	57	healing	healing	NN	B-NP
O	58	60	of	of	IN	B-PP
O	61	69	critical	critical	JJ	B-NP
O	69	70	-	-	HYPH	I-NP
O	70	74	size	size	NN	I-NP
B-Organ	75	84	calvarial	calvarial	JJ	I-NP
I-Organ	85	89	bone	bone	NN	I-NP
O	90	97	defects	defect	NNS	I-NP
O	97	98	.	.	.	O

O	99	106	Despite	Despite	IN	B-PP
O	107	110	the	the	DT	B-NP
O	111	123	insufficient	insufficient	JJ	I-NP
O	124	130	number	number	NN	I-NP
O	131	133	of	of	IN	B-PP
O	134	146	experimental	experimental	JJ	B-NP
O	147	154	studies	study	NNS	I-NP
O	154	155	,	,	,	O
B-Organism_substance	156	164	platelet	platelet	NN	B-NP
I-Organism_substance	164	165	-	-	HYPH	I-NP
I-Organism_substance	165	169	rich	rich	JJ	I-NP
I-Organism_substance	170	176	plasma	plasma	NN	I-NP
O	177	178	(	(	(	O
B-Organism_substance	178	181	PRP	PRP	NN	B-NP
O	181	182	)	)	)	O
O	183	192	including	include	VBG	B-PP
O	193	197	high	high	JJ	B-NP
O	198	205	amounts	amount	NNS	I-NP
O	206	208	of	of	IN	B-PP
O	209	215	growth	growth	NN	B-NP
O	216	223	factors	factor	NNS	I-NP
O	224	226	is	be	VBZ	B-VP
O	227	237	introduced	introduce	VBN	I-VP
O	238	240	to	to	TO	B-PP
O	241	249	clinical	clinical	JJ	B-NP
O	250	253	use	use	NN	I-NP
O	254	261	rapidly	rapidly	RB	B-ADVP
O	261	262	.	.	.	O

O	263	266	The	The	DT	B-NP
O	267	270	aim	aim	NN	I-NP
O	271	273	of	of	IN	B-PP
O	274	278	this	this	DT	B-NP
O	279	284	study	study	NN	I-NP
O	285	288	was	be	VBD	B-VP
O	289	291	to	to	TO	B-VP
O	292	299	compare	compare	VB	I-VP
O	300	303	the	the	DT	B-NP
O	304	311	effects	effect	NNS	I-NP
O	312	314	of	of	IN	B-PP
B-Organism_substance	315	318	PRP	PRP	NN	B-NP
O	319	322	and	and	CC	I-NP
B-Organism_substance	323	331	platelet	platelet	NN	I-NP
I-Organism_substance	331	332	-	-	HYPH	B-NP
I-Organism_substance	332	336	poor	poor	JJ	I-NP
I-Organism_substance	337	343	plasma	plasma	NN	I-NP
O	344	345	(	(	(	O
B-Organism_substance	345	348	PPP	PPP	NN	B-NP
O	348	349	)	)	)	O
O	350	352	on	on	IN	B-PP
O	353	360	healing	healing	NN	B-NP
O	361	363	of	of	IN	B-PP
O	364	372	critical	critical	JJ	B-NP
O	372	373	-	-	HYPH	I-NP
O	373	377	size	size	NN	I-NP
B-Organ	378	382	bone	bone	NN	I-NP
O	383	390	defects	defect	NNS	I-NP
O	390	391	.	.	.	O
O	391	400	Bilateral	Bilateral	JJ	B-NP
O	401	405	full	full	JJ	I-NP
O	405	406	-	-	HYPH	I-NP
O	406	415	thickness	thickness	NN	I-NP
O	415	416	,	,	,	O
O	417	425	critical	critical	JJ	B-NP
O	425	426	-	-	HYPH	I-NP
O	426	430	size	size	NN	I-NP
B-Organ	431	435	bone	bone	NN	I-NP
O	436	443	defects	defect	NNS	I-NP
O	444	448	were	be	VBD	B-VP
O	449	456	created	create	VBN	I-VP
O	457	459	in	in	IN	B-PP
O	460	463	the	the	DT	B-NP
B-Organ	464	472	parietal	parietal	JJ	I-NP
I-Organ	473	478	bones	bone	NNS	I-NP
O	479	481	of	of	IN	B-PP
O	482	484	32	32	CD	B-NP
O	485	492	rabbits	rabbit	NNS	I-NP
O	492	493	,	,	,	O
O	494	499	which	which	WDT	B-NP
O	500	503	had	have	VBD	B-VP
O	504	508	been	be	VBN	I-VP
O	509	516	studied	study	VBN	I-VP
O	517	519	in	in	IN	B-PP
O	520	521	4	4	CD	B-NP
O	522	528	groups	group	NNS	I-NP
O	528	529	.	.	.	O

O	530	536	Saline	Saline	NN	B-NP
O	536	537	,	,	,	O
O	538	546	thrombin	thrombin	NN	B-NP
O	547	555	solution	solution	NN	I-NP
O	555	556	,	,	,	O
B-Organism_substance	557	560	PPP	PPP	NN	B-NP
O	560	561	,	,	,	O
O	562	565	and	and	CC	O
B-Organism_substance	566	569	PRP	PRP	NN	B-NP
O	570	574	were	be	VBD	B-VP
O	575	582	applied	apply	VBN	I-VP
O	583	585	to	to	TO	B-PP
O	586	589	the	the	DT	B-NP
O	590	597	created	create	VBN	I-NP
O	598	605	defects	defect	NNS	I-NP
O	606	612	before	before	IN	B-PP
O	613	620	closure	closure	NN	B-NP
O	620	621	.	.	.	O

O	622	632	Radiologic	Radiologic	JJ	B-NP
O	633	639	defect	defect	NN	I-NP
O	640	644	area	area	NN	I-NP
O	645	656	measurement	measurement	NN	I-NP
O	657	664	results	result	VBZ	B-VP
O	665	667	at	at	IN	B-PP
O	668	669	0	0	CD	B-NP
O	669	670	,	,	,	I-NP
O	671	672	4	4	CD	I-NP
O	672	673	,	,	,	O
O	674	677	and	and	CC	O
O	678	680	16	16	CD	B-NP
O	681	686	weeks	week	NNS	I-NP
O	687	691	were	be	VBD	B-VP
O	692	700	compared	compare	VBN	I-VP
O	701	708	between	between	IN	B-PP
O	709	712	the	the	DT	B-NP
O	713	719	groups	group	NNS	I-NP
O	719	720	.	.	.	O

O	721	723	In	In	IN	B-PP
O	724	732	addition	addition	NN	B-NP
O	732	733	,	,	,	O
O	734	743	densities	density	NNS	B-NP
O	744	746	of	of	IN	B-PP
O	747	750	the	the	DT	B-NP
O	751	756	newly	newly	RB	I-NP
O	757	763	formed	form	VBN	I-NP
B-Organ	764	769	bones	bone	NNS	I-NP
O	770	772	at	at	IN	B-PP
O	773	777	16th	16th	JJ	B-NP
O	778	782	week	week	NN	I-NP
O	783	787	were	be	VBD	B-VP
O	788	795	studied	study	VBN	I-VP
O	795	796	.	.	.	O

O	797	807	Histologic	Histologic	JJ	B-NP
O	808	818	parameters	parameter	NNS	I-NP
O	819	820	(	(	(	O
O	820	827	primary	primary	JJ	B-NP
O	828	831	and	and	CC	I-NP
O	832	841	secondary	secondary	JJ	I-NP
B-Tissue	842	846	bone	bone	NN	I-NP
I-Tissue	847	856	trabecula	trabecula	NN	I-NP
O	856	857	,	,	,	O
O	858	876	neovascularization	neovascularization	NN	B-NP
O	876	877	,	,	,	O
O	878	881	and	and	CC	O
B-Multi-tissue_structure	882	886	bone	bone	NN	B-NP
I-Multi-tissue_structure	887	893	marrow	marrow	NN	I-NP
O	894	897	and	and	CC	O
B-Tissue	898	908	connective	connective	JJ	B-NP
I-Tissue	909	915	tissue	tissue	NN	I-NP
O	916	925	formation	formation	NN	I-NP
O	925	926	)	)	)	O
O	927	931	were	be	VBD	B-VP
O	932	940	compared	compare	VBN	I-VP
O	941	948	between	between	IN	B-PP
O	949	950	4	4	CD	B-NP
O	950	951	-	-	HYPH	I-NP
O	952	955	and	and	CC	I-NP
O	956	958	16	16	CD	I-NP
O	958	959	-	-	HYPH	I-NP
O	959	963	week	week	NN	I-NP
O	964	970	groups	group	NNS	I-NP
O	970	971	.	.	.	O
O	971	975	More	More	JJR	B-NP
O	976	981	rapid	rapid	JJ	I-NP
O	982	990	decrease	decrease	NN	I-NP
O	991	993	in	in	IN	B-PP
O	994	1000	defect	defect	NN	B-NP
O	1001	1005	size	size	NN	I-NP
O	1006	1009	was	be	VBD	B-VP
O	1010	1018	observed	observe	VBN	I-VP
O	1019	1021	in	in	IN	B-PP
O	1022	1028	groups	group	NNS	B-NP
O	1029	1030	3	3	CD	B-NP
O	1031	1034	and	and	CC	I-NP
O	1035	1036	4	4	CD	I-NP
O	1037	1041	than	than	IN	B-PP
O	1042	1044	in	in	IN	B-PP
O	1045	1051	groups	group	NNS	B-NP
O	1052	1053	1	1	CD	I-NP
O	1054	1057	and	and	CC	I-NP
O	1058	1059	2	2	CD	I-NP
O	1059	1060	,	,	,	O
O	1061	1065	both	both	CC	O
O	1066	1068	in	in	IN	B-PP
O	1069	1072	the	the	DT	B-NP
O	1073	1076	4th	4th	JJ	I-NP
O	1077	1080	and	and	CC	I-NP
O	1081	1085	16th	16th	JJ	I-NP
O	1086	1091	weeks	week	NNS	I-NP
O	1091	1092	.	.	.	O

O	1093	1098	Newly	Newly	RB	B-NP
O	1099	1105	formed	form	VBN	I-NP
B-Organ	1106	1110	bone	bone	NN	I-NP
O	1111	1120	densities	density	NNS	I-NP
O	1121	1125	were	be	VBD	B-VP
O	1126	1130	also	also	RB	I-VP
O	1131	1136	found	find	VBN	I-VP
O	1137	1139	to	to	TO	I-VP
O	1140	1142	be	be	VB	I-VP
O	1143	1149	higher	high	JJR	B-ADJP
O	1150	1152	in	in	IN	B-PP
O	1153	1158	these	these	DT	B-NP
O	1159	1160	2	2	CD	I-NP
O	1161	1167	groups	group	NNS	I-NP
O	1167	1168	.	.	.	O

O	1169	1172	New	New	JJ	B-NP
B-Organ	1173	1177	bone	bone	NN	I-NP
O	1178	1187	formation	formation	NN	I-NP
O	1188	1191	was	be	VBD	B-VP
O	1192	1200	detected	detect	VBN	I-VP
O	1201	1203	to	to	TO	I-VP
O	1204	1206	be	be	VB	I-VP
O	1207	1211	more	more	RBR	B-ADJP
O	1212	1217	rapid	rapid	JJ	I-ADJP
O	1218	1229	considering	consider	VBG	B-VP
O	1230	1240	histologic	histologic	JJ	B-NP
O	1241	1251	parameters	parameter	NNS	I-NP
O	1251	1252	,	,	,	O
O	1253	1255	in	in	IN	B-PP
O	1256	1262	groups	group	NNS	B-NP
O	1263	1264	3	3	CD	B-NP
O	1265	1268	and	and	CC	I-NP
O	1269	1270	4	4	CD	I-NP
O	1271	1273	at	at	IN	B-PP
O	1274	1277	4th	4th	JJ	B-NP
O	1278	1281	and	and	CC	I-NP
O	1282	1286	16th	16th	JJ	I-NP
O	1287	1292	weeks	week	NNS	I-NP
O	1292	1293	.	.	.	O
O	1293	1298	Study	Study	NNP	B-NP
O	1299	1311	demonstrates	demonstrate	VBZ	B-VP
O	1312	1316	that	that	IN	B-SBAR
B-Organism_substance	1317	1320	PRP	PRP	NN	B-NP
O	1321	1324	and	and	CC	I-NP
B-Organism_substance	1325	1328	PPP	PPP	NN	I-NP
O	1329	1334	might	might	MD	B-VP
O	1335	1339	have	have	VB	I-VP
O	1340	1349	favorable	favorable	JJ	B-NP
O	1350	1357	effects	effect	NNS	I-NP
O	1358	1360	on	on	IN	B-PP
B-Organ	1361	1365	bone	bone	NN	B-NP
O	1366	1373	healing	healing	NN	I-NP
O	1373	1374	.	.	.	O

O	1375	1383	Although	Although	IN	B-SBAR
O	1384	1386	we	we	PRP	B-NP
O	1387	1393	cannot	cannot	MD	B-VP
O	1394	1400	reveal	reveal	VB	I-VP
O	1401	1404	any	any	DT	B-NP
O	1405	1416	statistical	statistical	JJ	I-NP
O	1417	1427	difference	difference	NN	I-NP
O	1428	1435	between	between	IN	B-PP
O	1436	1441	these	these	DT	B-NP
O	1442	1443	2	2	CD	I-NP
O	1444	1454	substances	substance	NNS	I-NP
O	1455	1466	considering	consider	VBG	B-VP
O	1467	1481	osteoinductive	osteoinductive	JJ	B-NP
O	1482	1491	potential	potential	NN	I-NP
O	1491	1492	,	,	,	O
B-Organism_substance	1493	1496	PRP	PRP	NN	B-NP
O	1497	1502	group	group	NN	I-NP
O	1503	1506	has	have	VBZ	B-VP
O	1507	1519	demonstrated	demonstrate	VBN	I-VP
O	1520	1528	superior	superior	JJ	B-NP
O	1529	1536	results	result	NNS	I-NP
O	1537	1545	compared	compare	VBN	B-PP
O	1546	1550	with	with	IN	B-PP
O	1551	1557	fibrin	fibrin	NN	B-NP
O	1558	1562	glue	glue	NN	I-NP
O	1563	1568	group	group	NN	I-NP
O	1568	1569	.	.	.	O

O	1570	1576	Higher	High	JJR	B-NP
B-Cell	1577	1585	platelet	platelet	NN	I-NP
O	1586	1600	concentrations	concentration	NNS	I-NP
O	1601	1604	may	may	MD	B-VP
O	1605	1611	expose	expose	VB	I-VP
O	1612	1622	beneficial	beneficial	JJ	B-NP
O	1623	1630	effects	effect	NNS	I-NP
O	1631	1633	of	of	IN	B-PP
B-Organism_substance	1634	1637	PRP	PRP	NN	B-NP
O	1637	1638	.	.	.	O

